Selected research
Industry Research
Neoantigen Vaccine Industry Research Report 2026
Market perspective
The global Neoantigen Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neoantigen Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neoantigen Vaccine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neoantigen Vaccine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neoantigen Vaccine include Merck & Co Inc, Eli Lilly and Company, Pfizer, ZIOPHARM Oncology, Vaximm AG, Vaccibody AS, Roche Holding AG, OSE Immunotherapeutics and Novogene, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neoantigen Vaccine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neoantigen Vaccine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neoantigen Vaccine Market by Company
Merck & Co Inc
Eli Lilly and Company
Pfizer
ZIOPHARM Oncology
Vaximm AG
Vaccibody AS
Roche Holding AG
OSE Immunotherapeutics
Novogene
Nouscom
Moderna
Medigene AG
ISA Pharmaceuticals
Gritstone Bio
Genocea Biosciences Inc
BrightPath Biotherapeutics
BioNTech
Avidea Technologies
Agenus Inc
Advaxis
Neoantigen Vaccine Segment by Type
Personalized Vaccine
Off-the shelf Vaccine
Neoantigen Vaccine Segment by Application
Gastrointestinal Cancer
Lung Cancer
Melanoma Cancer
Brain Cancer
Others
Neoantigen Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neoantigen Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neoantigen Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neoantigen Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neoantigen Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Personalized Vaccine
- Off-the shelf Vaccine
Applications
- Gastrointestinal Cancer
- Lung Cancer
- Melanoma Cancer
- Brain Cancer
- Others
Companies covered
- Merck & Co Inc
- Eli Lilly and Company
- Pfizer
- ZIOPHARM Oncology
- Vaximm AG
- Vaccibody AS
- Roche Holding AG
- OSE Immunotherapeutics
- Novogene
- Nouscom
- Moderna
- Medigene AG
- ISA Pharmaceuticals
- Gritstone Bio
- Genocea Biosciences Inc
- BrightPath Biotherapeutics
- BioNTech
- Avidea Technologies
- Agenus Inc
- Advaxis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neoantigen Vaccine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Personalized Vaccine
- 2.2.3 Off-the shelf Vaccine
- 2.3 Neoantigen Vaccine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Gastrointestinal Cancer
- 2.3.3 Lung Cancer
- 2.3.4 Melanoma Cancer
- 2.3.5 Brain Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Neoantigen Vaccine Breakdown Data by Type
- 3.1 Global Neoantigen Vaccine Historic Market Size by Type (2021-2026)
- 3.2 Global Neoantigen Vaccine Forecasted Market Size by Type (2027-2032)
4 Neoantigen Vaccine Breakdown Data by Application
- 4.1 Global Neoantigen Vaccine Historic Market Size by Application (2021-2026)
- 4.2 Global Neoantigen Vaccine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neoantigen Vaccine Market Perspective (2021-2032)
- 5.2 Global Neoantigen Vaccine Growth Trends by Region
- 5.2.1 Global Neoantigen Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neoantigen Vaccine Historic Market Size by Region (2021-2026)
- 5.2.3 Neoantigen Vaccine Forecasted Market Size by Region (2027-2032)
- 5.3 Neoantigen Vaccine Market Dynamics
- 5.3.1 Neoantigen Vaccine Industry Trends
- 5.3.2 Neoantigen Vaccine Market Drivers
- 5.3.3 Neoantigen Vaccine Market Challenges
- 5.3.4 Neoantigen Vaccine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neoantigen Vaccine Players by Revenue
- 6.1.1 Global Top Neoantigen Vaccine Players by Revenue (2021-2026)
- 6.1.2 Global Neoantigen Vaccine Revenue Market Share by Players (2021-2026)
- 6.2 Global Neoantigen Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neoantigen Vaccine Head Office and Area Served
- 6.4 Global Neoantigen Vaccine Players, Product Type & Application
- 6.5 Global Neoantigen Vaccine Manufacturers Established Date
- 6.6 Global Neoantigen Vaccine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neoantigen Vaccine Market Size (2021-2032)
- 7.2 North America Neoantigen Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neoantigen Vaccine Market Size by Country (2021-2026)
- 7.4 North America Neoantigen Vaccine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neoantigen Vaccine Market Size (2021-2032)
- 8.2 Europe Neoantigen Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neoantigen Vaccine Market Size by Country (2021-2026)
- 8.4 Europe Neoantigen Vaccine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neoantigen Vaccine Market Size (2021-2032)
- 9.2 Asia-Pacific Neoantigen Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neoantigen Vaccine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neoantigen Vaccine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neoantigen Vaccine Market Size (2021-2032)
- 10.2 South America Neoantigen Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neoantigen Vaccine Market Size by Country (2021-2026)
- 10.4 South America Neoantigen Vaccine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neoantigen Vaccine Market Size (2021-2032)
- 11.2 Middle East & Africa Neoantigen Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neoantigen Vaccine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neoantigen Vaccine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co Inc
- 12.1.1 Merck & Co Inc Company Information
- 12.1.2 Merck & Co Inc Business Overview
- 12.1.3 Merck & Co Inc Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.1.4 Merck & Co Inc Neoantigen Vaccine Product Portfolio
- 12.1.5 Merck & Co Inc Recent Developments
- 12.2 Eli Lilly and Company
- 12.2.1 Eli Lilly and Company Company Information
- 12.2.2 Eli Lilly and Company Business Overview
- 12.2.3 Eli Lilly and Company Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.2.4 Eli Lilly and Company Neoantigen Vaccine Product Portfolio
- 12.2.5 Eli Lilly and Company Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.3.4 Pfizer Neoantigen Vaccine Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 ZIOPHARM Oncology
- 12.4.1 ZIOPHARM Oncology Company Information
- 12.4.2 ZIOPHARM Oncology Business Overview
- 12.4.3 ZIOPHARM Oncology Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.4.4 ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio
- 12.4.5 ZIOPHARM Oncology Recent Developments
- 12.5 Vaximm AG
- 12.5.1 Vaximm AG Company Information
- 12.5.2 Vaximm AG Business Overview
- 12.5.3 Vaximm AG Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.5.4 Vaximm AG Neoantigen Vaccine Product Portfolio
- 12.5.5 Vaximm AG Recent Developments
- 12.6 Vaccibody AS
- 12.6.1 Vaccibody AS Company Information
- 12.6.2 Vaccibody AS Business Overview
- 12.6.3 Vaccibody AS Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.6.4 Vaccibody AS Neoantigen Vaccine Product Portfolio
- 12.6.5 Vaccibody AS Recent Developments
- 12.7 Roche Holding AG
- 12.7.1 Roche Holding AG Company Information
- 12.7.2 Roche Holding AG Business Overview
- 12.7.3 Roche Holding AG Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.7.4 Roche Holding AG Neoantigen Vaccine Product Portfolio
- 12.7.5 Roche Holding AG Recent Developments
- 12.8 OSE Immunotherapeutics
- 12.8.1 OSE Immunotherapeutics Company Information
- 12.8.2 OSE Immunotherapeutics Business Overview
- 12.8.3 OSE Immunotherapeutics Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.8.4 OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio
- 12.8.5 OSE Immunotherapeutics Recent Developments
- 12.9 Novogene
- 12.9.1 Novogene Company Information
- 12.9.2 Novogene Business Overview
- 12.9.3 Novogene Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.9.4 Novogene Neoantigen Vaccine Product Portfolio
- 12.9.5 Novogene Recent Developments
- 12.10 Nouscom
- 12.10.1 Nouscom Company Information
- 12.10.2 Nouscom Business Overview
- 12.10.3 Nouscom Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.10.4 Nouscom Neoantigen Vaccine Product Portfolio
- 12.10.5 Nouscom Recent Developments
- 12.11 Moderna
- 12.11.1 Moderna Company Information
- 12.11.2 Moderna Business Overview
- 12.11.3 Moderna Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.11.4 Moderna Neoantigen Vaccine Product Portfolio
- 12.11.5 Moderna Recent Developments
- 12.12 Medigene AG
- 12.12.1 Medigene AG Company Information
- 12.12.2 Medigene AG Business Overview
- 12.12.3 Medigene AG Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.12.4 Medigene AG Neoantigen Vaccine Product Portfolio
- 12.12.5 Medigene AG Recent Developments
- 12.13 ISA Pharmaceuticals
- 12.13.1 ISA Pharmaceuticals Company Information
- 12.13.2 ISA Pharmaceuticals Business Overview
- 12.13.3 ISA Pharmaceuticals Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.13.4 ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio
- 12.13.5 ISA Pharmaceuticals Recent Developments
- 12.14 Gritstone Bio
- 12.14.1 Gritstone Bio Company Information
- 12.14.2 Gritstone Bio Business Overview
- 12.14.3 Gritstone Bio Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.14.4 Gritstone Bio Neoantigen Vaccine Product Portfolio
- 12.14.5 Gritstone Bio Recent Developments
- 12.15 Genocea Biosciences Inc
- 12.15.1 Genocea Biosciences Inc Company Information
- 12.15.2 Genocea Biosciences Inc Business Overview
- 12.15.3 Genocea Biosciences Inc Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.15.4 Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio
- 12.15.5 Genocea Biosciences Inc Recent Developments
- 12.16 BrightPath Biotherapeutics
- 12.16.1 BrightPath Biotherapeutics Company Information
- 12.16.2 BrightPath Biotherapeutics Business Overview
- 12.16.3 BrightPath Biotherapeutics Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.16.4 BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio
- 12.16.5 BrightPath Biotherapeutics Recent Developments
- 12.17 BioNTech
- 12.17.1 BioNTech Company Information
- 12.17.2 BioNTech Business Overview
- 12.17.3 BioNTech Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.17.4 BioNTech Neoantigen Vaccine Product Portfolio
- 12.17.5 BioNTech Recent Developments
- 12.18 Avidea Technologies
- 12.18.1 Avidea Technologies Company Information
- 12.18.2 Avidea Technologies Business Overview
- 12.18.3 Avidea Technologies Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.18.4 Avidea Technologies Neoantigen Vaccine Product Portfolio
- 12.18.5 Avidea Technologies Recent Developments
- 12.19 Agenus Inc
- 12.19.1 Agenus Inc Company Information
- 12.19.2 Agenus Inc Business Overview
- 12.19.3 Agenus Inc Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.19.4 Agenus Inc Neoantigen Vaccine Product Portfolio
- 12.19.5 Agenus Inc Recent Developments
- 12.20 Advaxis
- 12.20.1 Advaxis Company Information
- 12.20.2 Advaxis Business Overview
- 12.20.3 Advaxis Revenue in Neoantigen Vaccine Business (2021-2026)
- 12.20.4 Advaxis Neoantigen Vaccine Product Portfolio
- 12.20.5 Advaxis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst